Table 2.
MAb(s)a | Survival (%) |
Ab concn (μg/ml) for 50% survival | FICb | FIC indexc | ||
---|---|---|---|---|---|---|
Maximum | Minimum | 50% | ||||
Δ17F1 | 58.76 | 28.74 | 43.75 | 0.05 | ||
Δ20C1 | 124.55 | 33.88 | 79.22 | 0.18 | ||
Δ17F1 + 20C1 | 139.05 | 114.26 | 126.65 | 0.01 | 0.28 | |
Δ20C1 + 17F1 | 137.07 | 59.79 | 98.43 | 0.11 | 0.61 | 0.89 |
Δ17F1 | 60.35 | 28.96 | 44.65 | 0.40 | ||
Δ19C9 | 40.28 | 34.10 | 37.19 | 0.05 | ||
Δ17F1 + 19C9 | 55.28 | 31.18 | 43.23 | 0.18 | 0.45 | |
Δ19C9 + 17F1 | 60.21 | 40.63 | 50.42 | 1.25 | 25.50 | 25.96 |
Δ17E7 | 90.98 | 70.28 | 80.63 | 11.10 | ||
Δ19C9 | 84.71 | 66.93 | 75.82 | 39.80 | ||
Δ17E7 + 19C9 | 78.81 | 67.95 | 73.38 | 2.37 | 0.21 | |
Δ19C9 + 17E7 | 85.44 | 72.83 | 79.14 | 0.04 | 1,130.68 | 1,130.90 |
Δ20C1 | 54.30 | 17.00 | 35.65 | 2.95 | ||
ΔN5C10 | 63.58 | 15.88 | 39.73 | 0.43 | ||
Δ20C1 + N5C10 | 83.99 | 60.04 | 72.01 | 0.04 | 0.02 | |
ΔN5C10 + 20C1 | 90.58 | 39.48 | 65.03 | 0.08 | 0.20 | 0.21 |
Δ20C1 | 44.84 | 11.94 | 28.39 | 1.62 | ||
Δ19D9 | 73.42 | 12.31 | 42.86 | 1.79 | ||
Δ20C1 + 19D9 | 92.71 | 61.29 | 77.00 | 0.41 | 0.26 | |
Δ19D9 + 20C1 | 96.48 | 22.79 | 59.63 | 0.27 | 0.15 | 0.41 |
MAbs preceded by a Greek capital delta (Δ) are “variable antibodies,” i.e., used at various concentrations (see Fig. 4 and 5).
FIC was calculated as follows: Ab concentration of the variable antibody A that yields 50% of maximum cell survival when in combination with a constant concentration of antibody B divided by the Ab concentration at 50% of maximum cell survival with antibody A alone.